<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04831996</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 50465-109</org_study_id>
    <nct_id>NCT04831996</nct_id>
  </id_info>
  <brief_title>To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.</brief_title>
  <official_title>A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Parsaclisib in Participants With Normal Renal Function and Participants With Renal Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the pharmacokinetics and safety of parsaclisib in&#xD;
      participants With normal renal function and participants with renal impairment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 4, 2021</start_date>
  <completion_date type="Anticipated">February 3, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 29, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics Parameter Groups1-4 : Cmax of parsaclisib</measure>
    <time_frame>4 Days</time_frame>
    <description>Maximum Observed Plasma Concentration of parsaclisib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Parameter Groups 1-4 : AUC 0-∞ of parsaclisib</measure>
    <time_frame>4 Days</time_frame>
    <description>Area Under the Concentration-time Curve From 0 to Infinity of parsaclisib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Parameter Groups 1-4 : AUC(0-t) of parsaclisib</measure>
    <time_frame>4 Days</time_frame>
    <description>Area Under the concentration- time curve up to the last measurable concentration of parsaclisib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Parameter Group 5: Cmax of parsaclisib</measure>
    <time_frame>4 Days for period 1 and 2</time_frame>
    <description>Maximum Observed Plasma Concentration of parsaclisib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Parameter Group 5 : AUC 0-∞ of parsaclisib</measure>
    <time_frame>4 Days for period 1 and 2</time_frame>
    <description>Area Under the Concentration-time Curve From 0 to Infinity of parsaclisib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Parameter Group 5: AUC(0-t) of parsaclisib</measure>
    <time_frame>4 Days for period 1 and 2</time_frame>
    <description>Area Under the concentration- time curve up to the last measurable concentration of parsaclisib</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Treatment Emergent Adverse Events (TEAE) Groups 1-4</measure>
    <time_frame>up to 11 Days</time_frame>
    <description>Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameter Groups 1-4 : tmax of parsaclisib</measure>
    <time_frame>4 Days</time_frame>
    <description>Time to reach maximum plasma concentration of parsaclisib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameter Groups 1-4 : t1/2 of parsaclisib</measure>
    <time_frame>4 Days</time_frame>
    <description>Apparent terminal phase disposition half-life of parsaclisib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameter Groups 1-4 : CL/F of parsaclisib</measure>
    <time_frame>4 Days</time_frame>
    <description>Oral dose clearance of parsaclisib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameter Groups 1-4 : Vz/F of parsaclisib</measure>
    <time_frame>4 Days</time_frame>
    <description>Apparent oral dose volume of distribution of parsaclisib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameter Group 5 : tmax of parsaclisib</measure>
    <time_frame>4 Days for period 1 and 2</time_frame>
    <description>Time to reach maximum plasma concentration of parsaclisib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameter Group 5 : t1/2 of parsaclisib</measure>
    <time_frame>4 Days for period 1 and 2</time_frame>
    <description>Apparent terminal phase disposition half-life of parsaclisib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameter Group 5 : CL/F of parsaclisib</measure>
    <time_frame>4 Days for period 1 and 2</time_frame>
    <description>Oral dose clearance of parsaclisib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameter Group 5 : Vz/F of parsaclisib</measure>
    <time_frame>4 Days for period 1 and 2</time_frame>
    <description>Apparent oral dose volume of distribution of parsaclisib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameter Group 5 during Dialysis - : AUC1-5 of parsaclisib</measure>
    <time_frame>4 Days for period 1 and 2</time_frame>
    <description>Area Under the Concentration-time Curve From 1 to 5 hrs. of parsaclisib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Treatment Emergent Adverse Events (TEAE) Group 5</measure>
    <time_frame>up to 18 Days</time_frame>
    <description>Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Advanced Malignancies</condition>
  <arm_group>
    <arm_group_label>Treat Group 1 : Normal Renal Function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>eGFR: ≥ 90 mL/min/1.73 m^2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treat Group 2 : Mild Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>eGFR: 60-89 mL/min/1.73 m^2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treat Group 3 : Moderate Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>eGFR: 30-59 mL/min/1.73 m^2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treat Group 4 : Severe Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>eGFR: ≤ 29 mL/min/1.73 m^2 and not on Hemo Dialysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treat Group 5 : Kidney Failure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>eGFR: ≤ 29 mL/min/1.73 m^2 and on Hemo Dialysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>parsaclisib</intervention_name>
    <description>parsaclisib will be administered orally after 8 hours of fasting.</description>
    <arm_group_label>Treat Group 1 : Normal Renal Function</arm_group_label>
    <arm_group_label>Treat Group 2 : Mild Renal Impairment</arm_group_label>
    <arm_group_label>Treat Group 3 : Moderate Renal Impairment</arm_group_label>
    <arm_group_label>Treat Group 4 : Severe Renal Impairment</arm_group_label>
    <arm_group_label>Treat Group 5 : Kidney Failure</arm_group_label>
    <other_name>INCB050465</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants will be classified at screening by renal function based on eGFR as&#xD;
             calculated by the MDRD formula and requirement for HD (Group 5).&#xD;
&#xD;
          -  Participants eligible for Group 5 with ESRD have received HD for at least 3 months&#xD;
             prior to screening.&#xD;
&#xD;
          -  Participants eligible for Group 1 should be in good health as determined by no&#xD;
             clinically significant deviations from normal for medical history, physical&#xD;
             examination, vital signs, 12-lead ECGs, or clinical laboratory determinations at&#xD;
             screening or Day -1.&#xD;
&#xD;
          -  Participants eligible for Groups 2 through 5 may have medical findings consistent with&#xD;
             their degree of renal dysfunction.&#xD;
&#xD;
          -  Participants with abnormal findings considered not clinically significant by the&#xD;
             medical monitor or investigator are eligible.&#xD;
&#xD;
             0Body mass index within the range 18.0 to 40.0 kg/m2 (inclusive) at screening.&#xD;
&#xD;
          -  Willingness to avoid pregnancy or fathering children.&#xD;
&#xD;
          -  Ability to swallow and retain oral medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of uncontrolled or unstable cardiovascular, respiratory, hepatic,&#xD;
             gastrointestinal, endocrine, hematopoietic, psychiatric, and/or neurological disease&#xD;
             within 6 months of screening. Evidence of rapidly deteriorating renal function.&#xD;
&#xD;
          -  Participants who have a current, functioning organ transplant or have a scheduled&#xD;
             organ transplant within 6 weeks after check-in.&#xD;
&#xD;
          -  History of malignancy within 5 years of screening, with the exception of cured basal&#xD;
             cell carcinoma, squamous cell carcinoma of the skin, ductal carcinoma in situ, or&#xD;
             Gleason 6 prostate cancer.&#xD;
&#xD;
          -  History of clinically significant gastrointestinal disease or surgery (cholecystectomy&#xD;
             and appendectomy are allowed) that could impact the absorption of study drug.&#xD;
&#xD;
          -  Participants eligible for Group 1 who have a history of renal disease or renal injury&#xD;
             as indicated by an abnormal, clinically significant renal function profile at&#xD;
             screening or Day -1.&#xD;
&#xD;
          -  Participants eligible for Groups 2 through 5 who have had a change in disease status&#xD;
             within 30 days of screening, as documented by the participant's medical history,&#xD;
             deemed clinically significant by the investigator.&#xD;
&#xD;
          -  History or current diagnosis of uncontrolled or significant cardiac disease indicating&#xD;
             significant risk of safety for participation in the study.&#xD;
&#xD;
          -  Any major surgery within 4 weeks of screening.&#xD;
&#xD;
          -  Donation of blood to a blood bank within 4 weeks of screening (within 2 weeks for&#xD;
             plasma only).&#xD;
&#xD;
          -  Blood transfusion within 4 weeks of Day -1 (for Groups 1 through 4) or Period 1, Day&#xD;
&#xD;
          -  1 (Group 5).&#xD;
&#xD;
          -  Chronic or current active infectious disease requiring systemic antibiotic,&#xD;
             antifungal, or antiviral treatment.&#xD;
&#xD;
          -  Positive test for HBV (HBsAg, HBsAg antibody, and hepatitis B core antibody), HCV (HCV&#xD;
             antibody), or HIV. Participants whose results are compatible with prior immunization&#xD;
             for HBV may be included at the discretion of the investigator.&#xD;
&#xD;
        Participants eligible for Group 1 who have used tobacco- or nicotine-containing products&#xD;
        within 6 months of screening.&#xD;
&#xD;
          -  Participants eligible for Groups 2 through 5 who smoke &gt; 10 cigarettes per day or&#xD;
             equivalent use of other tobacco- or nicotine-containing products and are unwilling to&#xD;
             refrain from tobacco or nicotine use on dosing days and abide by CRU restrictions.&#xD;
&#xD;
          -  Positive breath test for ethanol or positive urine or serum screen for drugs of abuse&#xD;
             that is not otherwise explained by permitted concomitant medications.&#xD;
&#xD;
          -  Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) of&#xD;
             study drug administration with another investigational medication or current&#xD;
             enrollment in another investigational drug study.&#xD;
&#xD;
          -  Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) of&#xD;
             study drug administration with strong or moderate inducer or inhibitor of CYP3A4,&#xD;
             P-gp,or BCRP.&#xD;
&#xD;
          -  For participants eligible for Group 1, use of prescription drugs within 14 days of&#xD;
             study drug administration or nonprescription medications/products (including vitamins,&#xD;
             minerals, and phytotherapeutic/herbal/plant-derived preparations) within 7 days of&#xD;
             study drug administration. However, occasional paracetamol, ibuprofen, and&#xD;
             standard-dose vitamins are permitted.&#xD;
&#xD;
          -  For participants eligible for Groups 2 through 5, use of prescription drugs within 14&#xD;
             days of study drug administration, with the exception of established therapy for renal&#xD;
             disease and the treatment of associated disorders that have been stable for at least 7&#xD;
             days prior to study drug administration, as approved by the investigator and in&#xD;
             consultation with the sponsor's medical monitor.&#xD;
&#xD;
          -  Current or recent history (within 30 days before screening) of a clinically&#xD;
             significant bacterial, fungal, parasitic, or mycobacterial infection, or currently&#xD;
             receiving systemic antibiotics. Current clinically significant viral infection at&#xD;
             screening or check-in.&#xD;
&#xD;
          -  History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) deemed&#xD;
             clinically relevant by the investigator.&#xD;
&#xD;
          -  Inability to undergo venipuncture or tolerate venous access.&#xD;
&#xD;
          -  Participants eligible for Group 5 that are not expected to continue HD treatment for&#xD;
             the duration of the study.&#xD;
&#xD;
          -  Receipt of live (including attenuated) vaccines or anticipation of need for such a&#xD;
             vaccine during the study (Note: nonlive or inactivated vaccines are allowed up to 2&#xD;
             weeks prior to the first dose of study drug).&#xD;
&#xD;
          -  Known hypersensitivity or severe reaction to parsaclisib or excipients of parsaclisib.&#xD;
&#xD;
          -  History of alcoholism within 3 months of screening.&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>82 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Incyte Corporation Call Center (US)</last_name>
    <phone>1.855.463.3463</phone>
    <email>medinfo@incyte.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Incyte Corporation Call Center (ex-US)</last_name>
    <phone>+800 00027423</phone>
    <email>eumedinfo@incyte.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prism Research</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 2, 2021</study_first_submitted>
  <study_first_submitted_qc>April 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2021</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.</ipd_time_frame>
    <ipd_access_criteria>Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.incyte.com/our-company/compliance-and-transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

